🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “First Tracks Biotherapeutics” Clear

  1. Remimazolam Besylate

    First Tracks Biotherapeutics

    Critical Illness; Mechanical Ventilation; Shock

    phase 3 small molecule active

    1 trial

  2. Rifaximin

    First Tracks Biotherapeutics

    Crohn Disease

    phase 3 small molecule active

    1 trial

  3. Rituximab

    First Tracks Biotherapeutics

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    3 trials

  4. Rituximab

    First Tracks Biotherapeutics

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. Robotic Gastrectomy

    First Tracks Biotherapeutics

    Gastric Cancer (GC)

    phase 3 other active

    1 trial

  6. S-1 therapy

    First Tracks Biotherapeutics

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  7. Sorafenib

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  8. Suxiao Jiuxin Pill

    First Tracks Biotherapeutics

    Acute Mountain Sickness

    phase 3 small molecule active

    1 trial

  9. TNK-tPA

    First Tracks Biotherapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  10. The methylprednisolone sodium succinate

    First Tracks Biotherapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  11. Tiaoshen Anti-cancer Granules

    First Tracks Biotherapeutics

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  12. Tinidazole oral microneedle patch

    First Tracks Biotherapeutics

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  13. Tislelizumab

    First Tracks Biotherapeutics

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  14. Tislelizumab + SOX Chemotherapy

    First Tracks Biotherapeutics

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  15. Tranexamic acid

    First Tracks Biotherapeutics

    Hemorrhage, Postpartum

    phase 3 small molecule completed

    1 trial

  16. Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.

    First Tracks Biotherapeutics

    Post-stroke Epilepsy

    phase 3 small molecule active

    1 trial

  17. Triptorelin for Injection

    First Tracks Biotherapeutics

    Ovarian Hyperstimulation Syndrome

    phase 3 small molecule active

    1 trial

  18. Trophic enteral feeding combined with supplemental parenteral nutrition

    First Tracks Biotherapeutics

    Severe Stroke

    phase 3 other active

    1 trial

  19. Two Anti-angiogenesis Drugs（Endostar and Thalidomide）

    First Tracks Biotherapeutics

    Colorectal Neoplasms

    phase 3 small molecule active

    1 trial

  20. Tyrosine kinase inhibitor (TKIs)

    First Tracks Biotherapeutics

    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  21. UDCA

    First Tracks Biotherapeutics

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  22. Ustekinumab

    First Tracks Biotherapeutics

    Crohn Disease

    phase 3 small molecule active

    1 trial

  23. Venetoclax

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  24. Venetoclax in combination with fludarabine and melphalan

    First Tracks Biotherapeutics

    Venentoclax

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources